

# **Key Investor Information Document**



This document provides you with key investor information for this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

Only French version has legal validity — In case of dispute, only the French version shall prevail between the parties

# EXANE ARCHIMEDES FUND – CLASS B USD (CODE ISIN: LU1448083391) A sub-fund of the Exane Funds 1 Luxembourg SICAV The fund is managed by Exane Asset Management

### **OBJECTIVE AND INVESTMENT POLICY**

**Investment objective**: Exane Archimedes Fund (hereinafter "Archimedes") seeks to deliver an absolute and regular return decorrelated from the financial markets by means of dynamic "long/short equity" investment management.

**Investment strategy:** Archimedes is managed on a discretionary basis, depending on the Investment Manager's expectations.

The investment strategy consists in simultaneously managing a portfolio of long positions on companies considered to be undervalued, and a portfolio of short positions on companies considered to be overvalued. These transactions constitute an arbitrage technique that reduces Archimedes' exposure to market risk or to a specific sectoral risk. The risk generated by one or more exposures to a downturn in share prices should not be viewed in isolation but should be considered in the context of the overall portfolio and similar securities held by the Sub-fund in long positions. The risk associated with a sale of securities in this context is thus not absolute, but should always be considered as a relative risk.

Investment universe: In regional terms, the investment universe is international but focuses predominantly on European stocks. In sectoral terms, the majority of positions are concentrated in telecommunications sector in the broadest sense of the term in particular telecommunications operators and equipment manufacturers; technology sector in the broadest sense of the term in particular software and information technology services, semiconductors, electronics and the internet; utilities sector in the broadest sense of the term.

**Minimum recommended investment term:** Archimedes may be unsuitable for investors wishing to withdraw their investment within two years.

Archimedes is an accumulation fund.

Potential leverage: The Investment Manager may use financial contracts to gain synthetic exposure to a company or market. The potential leverage resulting from these financial contracts is limited to 100% of the assets.

Net exposure of the portfolio: The portfolio's net exposure to equity market risk (long positions less short positions) is between -10% and 35%. This limited exposure to equity market risk aims in particular to maintain both low performance volatility and low correlation with equity indices.

**Option of redeeming shares subscribed:** investors may request the redemption of their shares before 4pm on each Paris stock market trading day.

## **RISK AND RETURN PROFILE**



The synthetic indicator rates Archimedes on a scale of 1 to 7, but the risk category with which Archimedes is associated is not guaranteed and may change over time. The synthetic indicator was produced using past volatility records.

Archimedes has been placed in this category because of its diversified exposure to equity risk.

The lowest risk category does not mean "risk free".

Archimedes does not provide any guarantee of capital invested. Investors may not get back all the money they have invested.

Risks to which the Fund is exposed that have not been adequately taken into account by the indicator and could result in a fall in the net asset value:

Counterparty risk: Archimedes may incur losses through its commitments vis-à-vis a counterparty in connection with its swaps, CFDs, forward contracts, and borrowing and lending of securities in the event of the counterparty's default or its inability to fulfil its contractual obligations.

**Credit risk:** Archimedes is invested in debt securities issued by firstrate issuers that may nevertheless find themselves in the position of being unable to fulfil their commitments.

Please see the Fund's prospectus for further information about risks.





# **Key Investor Information Document**



## **CHARGES FOR CLASS B USD**

The charges and fees payable are used to cover the Fund's operating expenses, including the cost of marketing and distributing the shares. These charges limit the potential growth of the investments

One-off charges taken before or after you invest Entry charges Max 5% Exit charges None The percentage indicated above is the maximum that can be taken from your capital before it is invested Charges taken by the Fund over one year Ongoing 2.12 % TTC charges Charges taken by the Fund under specific conditions Maximum 20%, including all taxes, of performance exceeding the Fed Fund Effective Rate + 1% of Performance annual performance with application of a High Water fee Mark mechanism. Amount of performance fee invoiced for the last Class B USD is intended for all investors.

The entry and exit charges indicated above are always maximum figures. In some cases investors will pay less than these amounts. Investors can obtain a statement of the actual amounts of entry and exit charges from their financial advisors.

Please see section IX of the prospectus on and section 12 of the supplement relating to Archimedes for further information about charges and fees and the High Water Mark mechanism applicable to the performance fees.

Ongoing charges do not include performance fees and transaction charges. The rate of the ongoing charges is based on the ongoing charges invoiced estimated and may vary from one year to the next.

## PAST PERFORMANCES FOR CLASS B USD

Data non available.

#### PRATICAL INFORMATIONS

financial year: None

Class	ISIN Code	Target subscriber profile	Currency	Minimum initial investment	Minimum subsequent investment	Appropriation of income
Α	LU0417733242	Institutional Investors	Euro	125.000 euro	None	Accumulation
A USD	LU0548301901	Institutional Investors	USD	125.000 dollari USA	None	Accumulation
В	LU0417733325	All investors.	Euro	1 Azione	None	Accumulation
B USD	LU1448083391	All investors.	USD	1 Azione	None	Accumulation
E	LU1155061614	Institutional Investors	Euro	50.000.000 euro	None	Accumulation

The SICAV's prospectus, annual and half-year reports, and any practical information such as the latest net asset values for each Class, are available from the SICAV's registered office, and on the investment manager's website at the following address: http://www.exane-am.com/en/funds/archimedes

Custodian and Administrative Agent BNP Paribas Securities Services 60, avenue J.F. Kennedy

L-1855 Luxembourg

The details of the up-to-date remuneration policy of the Management Company are available on:

#### https://www.exane-am.com/sites/default/files/eamdocs/EAM-PR.pdf;

a paper copy is available free of charge upon request to the registered office of the Management Company.

Unless the SICAV's documents of incorporation provide otherwise, investors' and creditors' rights in relation to a sub-fund are limited to the assets of this sub-fund as the assets and liabilities of each sub-fund are kept separate.

Investors are advised that the tax legislation in Archimedes' country of origin may affect their personal tax position.

Exane Funds 1 will only accept liability for statements made in this document that are misleading or inaccurate, or are inconsistent with the corresponding parts of the Archimedes prospectus.

Archimedes may comprise other types of shares. Investors can find more information on these shares in Archimedes' full prospectus or on the Investment Manager's website at the address indicated above.

Shareholders may ask to convert all or some of the shares they hold in a Class of a given sub-fund into shares of another Class of the same sub-fund or another sub-fund, provided that the currency of the shares of the other Class is the same. For further details, shareholders should refer to Section VI 4 of the Prospectus.

Archimedes has been approved in Luxembourg and authorised for marketing by Luxembourg's financial sector regulator, the Commission de Surveillance du Secteur Financier. The Investment Manager, Exane Asset Management, has been approved in France and is regulated by France's financial markets authority, the Autorité des Marchés Financiers, under no. GP01015.

No class of shares may be offered or sold to "US person" as defined by Regulation S of the US securities Act of 1933 who are unauthorised persons within the meaning of Article 11 of the Company's Articles of Incorporation

The key information for investors provided in this document was correct and up to date as of 10 February 2017.

